CORT / Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2022 Results - Earnings Call Transcript

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023. more_horizontal

MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter fi more_horizontal

Corcept Therapeutics' equity stock shows promising investment prospects with the resolution of its Korlym overhang and strong financial performance. T more_horizontal

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its pro more_horizontal

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, more_horizontal

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guid more_horizontal

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Fi more_horizontal

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compare more_horizontal